PTPA and neoplasm: Based on the results of a PP2A agonist inhibiting ERK activation and the proliferation of DP thymocytes in a carcinogen‐induced tumor model, a targeting this axis may also be useful to reprogram PP2A‐ERK axis and enhance the efficacy of limiting tumorigenic DP thymocyte proliferation in thymic lymphoma.